Table 4.
Baseline characteristics of the LAT and LA-SEC patient populations.
| Variables | LAT (n = 55) | LAECS (n = 178) | P-value |
|---|---|---|---|
| Age, years | 67.1 ± 8.9 | 67.2 ± 8.4 | 0.946 |
| Male sex, n (%) | 33 (60.0) | 119 (66.9) | 0.418 |
| Per-AF, n (%) | 52 (94.5) | 151 (84.8) | 0.067 |
| AF history, years | 3.8 ± 5.5 | 3.8 ± 5.6 | 0.973 |
| Hypertension, n (%) | 26 (47.3) | 118 (66.3) | 0.017 |
| Diabetes mellitus, n (%) | 6 (10.9) | 32 (18.0) | 0.296 |
| Congestive heart failure, n (%) | 12 (21.8) | 22 (12.4) | 0.124 |
| Previous stroke/TIA, n (%) | 2 (3.6) | 38 (21.3) | 0.002 |
| Coronary artery disease, n (%) | 4 (7.3) | 25 (14.0) | 0.244 |
| Age ≥ 65 | 35 (63.6) | 117 (65.7) | 0.871 |
| Age ≥ 75 | 11 (20.0) | 33 (18.5) | 0.844 |
| CHA2DS2-VASc score, n (%) | 2.6 ± 1.4 | 3.0 ± 1.7 | 0.080 |
| 0 | 4 (7.3) | 7 (3.9) | 0.293 |
| 1 | 9 (26.4) | 36 (20.2) | 0.696 |
| ≥ 2 | 42 (76.4) | 135 (75.8) | 1.000 |
| Serum uric acid, μmol/L | 427.7 ± 120.1 | 399.8 ± 114.5 | 0.120 |
| Male | 467.8 ± 134.0 | 417.1 ± 115.7 | 0.033 |
| Female | 367.5 ± 58.2 | 365.0 ± 104.4 | 0.913 |
| Creatinine, μmol/L | 79.6 ± 22.4 | 79.6 ± 20.2 | 0.996 |
| Hematocrit, % | 45.7 ± 17.4 | 43.8 ± 6.2 | 0.219 |
| Platelets (103/μL) | 178.1 ± 68.5 | 189.3 ± 61.4 | 0.249 |
| BNP | 592.2 ± 624.9 | 336.8 ± 281.3 | 0.005 |
| INR | 1.25 ± 0.53 | 1.32 ± 0.58 | 0.452 |
| INR ≥2.0, n (%) | 6 (10.9) | 21 (11.8) | 1.000 |
| Warfarin use, n (%) | 14 (25.5) | 53 (29.8) | 0.611 |
| NOAC, n (%) | 1 (1.8) | 12 (6.7) | 0.310 |
| Aspirin, n (%) | 3 (5.5) | 4 (2.2) | 0.360 |
| LAd, mm | 48.8 ± 7.3 | 47.1 ± 5.0 | 0.122 |
| LVDd, mm | 51.5 ± 7.7 | 49.6 ± 5.7 | 0.095 |
| LVEF, % | 55.7 ± 12.4 | 57.5 ± 8.4 | 0.316 |
| >Mild MR, n (%) | 23 (41.8) | 48 (27.0) | 0.044 |